Diabetic Retinopathy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diabetic Retinopathy – Pipeline Review, H2 2017’, provides an overview of the Diabetic Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy

The report reviews pipeline therapeutics for Diabetic Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Retinopathy therapeutics and enlists all their major and minor projects

The report assesses Diabetic Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Retinopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abzena Plc

Acucela Inc

Aerie Pharmaceuticals Inc

Aerpio Therapeutics Inc

Antisense Therapeutics Ltd

AntriaBio Inc

BCN Peptides SA

Boehringer Ingelheim GmbH

Charlesson LLC

Coherus BioSciences Inc

Crinetics Pharmaceuticals Inc

Dimerix Bioscience Pty Ltd

Dynamis Therapeutics Inc

EyeGene Inc

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals LLC

Icon Bioscience Inc

Islet Sciences Inc

Kodiak Sciences Inc

Kowa Co Ltd

Lupin Ltd

M's Science Corp

Mabion SA

Navigen Inc

Nemus Bioscience Inc

Oculis ehf

Ohr Pharmaceutical Inc

PanOptica Inc

Profarma

Promedior Inc

Regeneron Pharmaceuticals Inc

Ribomic Inc

Strongbridge Biopharma plc

Sylentis SAU

ThromboGenics NV

VESSL Therapeutics Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Retinopathy - Overview 8

Diabetic Retinopathy - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Diabetic Retinopathy - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 25

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Diabetic Retinopathy - Companies Involved in Therapeutics Development 33

Abzena Plc 33

Acucela Inc 33

Aerie Pharmaceuticals Inc 33

Aerpio Therapeutics Inc 34

Antisense Therapeutics Ltd 34

AntriaBio Inc 35

BCN Peptides SA 35

Boehringer Ingelheim GmbH 35

Charlesson LLC 36

Coherus BioSciences Inc 36

Crinetics Pharmaceuticals Inc 37

Dimerix Bioscience Pty Ltd 37

Dynamis Therapeutics Inc 38

EyeGene Inc 38

F. Hoffmann-La Roche Ltd 39

Foresee Pharmaceuticals LLC 39

Icon Bioscience Inc 39

Islet Sciences Inc 40

Kodiak Sciences Inc 40

Kowa Co Ltd 40

Lupin Ltd 41

M's Science Corp 41

Mabion SA 42

Navigen Inc 42

Nemus Bioscience Inc 42

Oculis ehf 43

Ohr Pharmaceutical Inc 43

PanOptica Inc 43

Profarma 44

Promedior Inc 44

Regeneron Pharmaceuticals Inc 45

Ribomic Inc 45

Strongbridge Biopharma plc 45

Sylentis SAU 46

ThromboGenics NV 46

VESSL Therapeutics Ltd 47

Diabetic Retinopathy - Drug Profiles 48

(irbesartan + propagermanium) - Drug Profile 48

A-717 - Drug Profile 52

AB-402 - Drug Profile 53

AC-301 - Drug Profile 54

aflibercept - Drug Profile 55

aflibercept biosimilar - Drug Profile 66

AKB-9778 - Drug Profile 67

Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile 72

APTA-1004 - Drug Profile 73

Aptamers for Diabetic Retinopathy - Drug Profile 74

AQA-001 - Drug Profile 75

AR-13154 - Drug Profile 76

atesidorsen sodium - Drug Profile 77

BI-1467335 - Drug Profile 84

BI-690517 - Drug Profile 86

Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 87

BNN-27 - Drug Profile 88

Cell Therapy for Diabetic Retinopathy - Drug Profile 89

CLT-005 - Drug Profile 90

CLT-020 - Drug Profile 91

CRN-00808 - Drug Profile 92

cyclosporine - Drug Profile 94

Cyndacel-M - Drug Profile 95

DRGT-109 - Drug Profile 97

DT-23552 - Drug Profile 98

DYN-12 - Drug Profile 99

E-1086 - Drug Profile 101

EG-Mirotin - Drug Profile 102

emixustat hydrochloride - Drug Profile 103

fenofibrate - Drug Profile 108

FP-008 - Drug Profile 109

Gene Therapy for Diabetic Retinopathy - Drug Profile 110

GLY-230 - Drug Profile 111

HCB-1019 - Drug Profile 112

IVMED-60 - Drug Profile 113

JP-153 - Drug Profile 114

KSI-301 - Drug Profile 115

magacizumab - Drug Profile 116

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile 118

MS-553 - Drug Profile 119

NB-2222 - Drug Profile 120

NM-108 - Drug Profile 122

OC-410 - Drug Profile 123

ocriplasmin - Drug Profile 124

OCU-200 - Drug Profile 130

OCX-063 - Drug Profile 131

PAN-90806 - Drug Profile 132

Peptagon - Drug Profile 134

PF-07 - Drug Profile 135

PRM-167 - Drug Profile 136

Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 138

ranibizumab biosimilar - Drug Profile 139

ranibizumab biosimilar - Drug Profile 140

ranibizumab biosimilar - Drug Profile 142

RBM-008 - Drug Profile 143

Recombinant Protein for Oncology, Diabetic Retinopathy and Retinopathy Of Prematurity - Drug Profile 144

Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile 145

Recombinant Proteins to Inhibit VEGFA for Diabetic Retinopathy - Drug Profile 146

Resolvine ER - Drug Profile 147

ripasudil - Drug Profile 148

RO-5461111 - Drug Profile 150

RT-001 - Drug Profile 151

RT-002 - Drug Profile 153

SBT-200 - Drug Profile 154

Small Molecules to Inhibit ARF6 for Macular Degeneration and Diabetic Retinopathy - Drug Profile 155

somatostatin - Drug Profile 156

squalamine lactate - Drug Profile 157

Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 165

Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile 166

SYL-136001v10 - Drug Profile 167

THR-687 - Drug Profile 168

Vaxier-001 - Drug Profile 169

veldoreotide - Drug Profile 170

Wnt-001 - Drug Profile 173

Diabetic Retinopathy - Dormant Projects 174

Diabetic Retinopathy - Discontinued Products 178

Diabetic Retinopathy - Product Development Milestones 179

Featured News & Press Releases 179

Appendix 189

Methodology 189

Coverage 189

Secondary Research 189

Primary Research 189

Expert Panel Validation 189

Contact Us 189

Disclaimer 190

List of Tables

List of Tables

Number of Products under Development for Diabetic Retinopathy, H2 2017 14

Number of Products under Development by Companies, H2 2017 16

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19

Number of Products under Development by Universities/Institutes, H2 2017 20

Products under Development by Companies, H2 2017 21

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 23

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 24

Products under Development by Universities/Institutes, H2 2017 25

Number of Products by Stage and Target, H2 2017 27

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 28

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 29

Number of Products by Stage and Mechanism of Action, H2 2017 31

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 32

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 33

Number of Products by Stage and Route of Administration, H2 2017 35

Number of Products by Stage and Molecule Type, H2 2017 37

Diabetic Retinopathy – Pipeline by Abzena Plc, H2 2017 38

Diabetic Retinopathy – Pipeline by Acucela Inc, H2 2017 38

Diabetic Retinopathy – Pipeline by Aerie Pharmaceuticals Inc, H2 2017 39

Diabetic Retinopathy – Pipeline by Aerpio Therapeutics Inc, H2 2017 39

Diabetic Retinopathy – Pipeline by Antisense Therapeutics Ltd, H2 2017 40

Diabetic Retinopathy – Pipeline by AntriaBio Inc, H2 2017 40

Diabetic Retinopathy – Pipeline by BCN Peptides SA, H2 2017 40

Diabetic Retinopathy – Pipeline by Boehringer Ingelheim GmbH, H2 2017 41

Diabetic Retinopathy – Pipeline by Charlesson LLC, H2 2017 41

Diabetic Retinopathy – Pipeline by Coherus BioSciences Inc, H2 2017 42

Diabetic Retinopathy – Pipeline by Crinetics Pharmaceuticals Inc, H2 2017 42

Diabetic Retinopathy – Pipeline by Dimerix Bioscience Pty Ltd, H2 2017 43

Diabetic Retinopathy – Pipeline by Dynamis Therapeutics Inc, H2 2017 43

Diabetic Retinopathy – Pipeline by EyeGene Inc, H2 2017 43

Diabetic Retinopathy – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 44

Diabetic Retinopathy – Pipeline by Foresee Pharmaceuticals LLC, H2 2017 44

Diabetic Retinopathy – Pipeline by Icon Bioscience Inc, H2 2017 45

Diabetic Retinopathy – Pipeline by Islet Sciences Inc, H2 2017 45

Diabetic Retinopathy – Pipeline by Kodiak Sciences Inc, H2 2017 45

Diabetic Retinopathy – Pipeline by Kowa Co Ltd, H2 2017 46

Diabetic Retinopathy – Pipeline by Lupin Ltd, H2 2017 46

Diabetic Retinopathy – Pipeline by M's Science Corp, H2 2017 46

Diabetic Retinopathy – Pipeline by Mabion SA, H2 2017 47

Diabetic Retinopathy – Pipeline by Navigen Inc, H2 2017 47

Diabetic Retinopathy – Pipeline by Nemus Bioscience Inc, H2 2017 48

Diabetic Retinopathy – Pipeline by Oculis ehf, H2 2017 48

Diabetic Retinopathy – Pipeline by Ohr Pharmaceutical Inc, H2 2017 48

Diabetic Retinopathy – Pipeline by PanOptica Inc, H2 2017 49

Diabetic Retinopathy – Pipeline by Profarma, H2 2017 49

Diabetic Retinopathy – Pipeline by Promedior Inc, H2 2017 49

Diabetic Retinopathy – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 50

Diabetic Retinopathy – Pipeline by Ribomic Inc, H2 2017 50

Diabetic Retinopathy – Pipeline by Strongbridge Biopharma plc, H2 2017 51

Diabetic Retinopathy – Pipeline by Sylentis SAU, H2 2017 51

Diabetic Retinopathy – Pipeline by ThromboGenics NV, H2 2017 52

Diabetic Retinopathy – Pipeline by VESSL Therapeutics Ltd, H2 2017 52

Diabetic Retinopathy – Dormant Projects, H2 2017 179

Diabetic Retinopathy – Dormant Projects, H2 2017 (Contd..1), H2 2017 180

Diabetic Retinopathy – Dormant Projects, H2 2017 (Contd..2), H2 2017 181

Diabetic Retinopathy – Dormant Projects, H2 2017 (Contd..3), H2 2017 182

Diabetic Retinopathy – Discontinued Products, H2 2017 183

List of Figures

List of Figures

Number of Products under Development for Diabetic Retinopathy, H2 2017 14

Number of Products under Development by Companies, H2 2017 15

Number of Products by Top 10 Targets, H2 2017 26

Number of Products by Stage and Top 10 Targets, H2 2017 26

Number of Products by Top 10 Mechanism of Actions, H2 2017 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 30

Number of Products by Routes of Administration, H2 2017 34

Number of Products by Stage and Routes of Administration, H2 2017 34

Number of Products by Top 10 Molecule Types, H2 2017 36

Number of Products by Stage and Top 10 Molecule Types, H2 2017 36

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports